Courage Therapeutics
PrivateLast Round
Seed
Nov 3, 2025
Total Funding Raised
$19.8M
Company Overview
Courage Therapeutics is a biopharmaceutical company that develops medicines targeting obesity and restrictive eating disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Courage Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Courage Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 3, 2025 | ||||
| Seed | May 16, 2025 | ||||
| Grant | Apr 22, 2021 | ||||
| Seed | Mar 24, 2021 |
Courage Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Mental Health | Grant |
| Arsenal Bridge Ventures | Seed |
| MIT Alumni Angels | Seed |
| Michigan Biomedical Venture Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2025
$7.8M round completed.
Courage Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Courage Therapeutics's valuation, stock price, and market status.
